Compare Aecom (ACM) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aecom vs Incyte Corporation — how do they compare? Aecom trades at $67.98 (market cap $8.69B), while Incyte Corporation trades at $116.69 (market cap $23.10B). The key difference: Incyte Corporation is far larger — about 2.7× Aecom's market cap, and Aecom pays a 1.76% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ACM | INCY | |
|---|---|---|
Market Cap | $8.69B | $23.10B |
Sector | Industrials | Health |
52-Week High | $134.35 | $118.05 |
52-Week Low | $66.86 | $67.38 |
Enterprise Value | $10.88B | $19.12B |
Dividend Yield | 1.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM trades at $67.64, down 0.15% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.53 and P/S of 0.57, while recent earnings beat expectations in Q1 2026. Analyst consensus is bullish with a $98.83 price target, though recent news includes both contract wins and legal investigations.
The outlook for ACM is mixed: strong valuation metrics and recent contract awards support upside potential, but technical weakness and legal scrutiny pose near-term risks. Earnings growth and margin expansion remain key catalysts, while investor sentiment is cautious due to the stock's 21% decline over the past three months.
Incyte (INCY) trades at $118.05, up 1.02% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion and a robust net margin of 26.71%. Recent catalysts include the acquisition of Vega Therapeutics and positive regulatory updates for Opzelura in Europe, supporting momentum.
The outlook remains positive given earnings beats, expanding product portfolio, and analyst consensus leaning buy. Key risks include reliance on key drugs, regulatory hurdles, and competitive pressures. The stock trades above the consensus price target of $109.14, suggesting near-term consolidation potential amid overbought RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
